Brokerages predict that ZEALAND PHARMA/S (NASDAQ:ZEAL) will report earnings per share (EPS) of ($0.69) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ZEALAND PHARMA/S’s earnings. ZEALAND PHARMA/S reported earnings of ($0.58) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 19%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 6th.

On average, analysts expect that ZEALAND PHARMA/S will report full year earnings of ($2.47) per share for the current year. For the next year, analysts forecast that the firm will report earnings of ($1.98) per share, with EPS estimates ranging from ($2.26) to ($1.69). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for ZEALAND PHARMA/S.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last announced its quarterly earnings results on Thursday, November 15th. The company reported $4.69 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $5.20. ZEALAND PHARMA/S had a negative net margin of 483.00% and a positive return on equity of 91.98%.

Several equities research analysts have commented on the stock. Needham & Company LLC set a $26.00 price objective on shares of ZEALAND PHARMA/S and gave the company a “buy” rating in a report on Friday, August 17th. Morgan Stanley set a $29.00 price objective on shares of ZEALAND PHARMA/S and gave the stock a “buy” rating in a research report on Wednesday, September 12th. MED restated a “positive” rating on shares of ZEALAND PHARMA/S in a research report on Thursday, September 27th. Finally, ValuEngine cut shares of ZEALAND PHARMA/S from a “hold” rating to a “sell” rating in a research report on Friday, November 16th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $29.00.

ZEAL traded up $0.68 during trading on Friday, hitting $12.38. 513 shares of the company traded hands, compared to its average volume of 6,770. The firm has a market cap of $392.48 million, a P/E ratio of -8.41 and a beta of 2.32. ZEALAND PHARMA/S has a one year low of $11.51 and a one year high of $18.91.


Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Further Reading: Find a Trading Strategy That Works

Get a free copy of the Zacks research report on ZEALAND PHARMA/S (ZEAL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with's FREE daily email newsletter.